We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,730.00
Bid: 1,730.00
Ask: 1,730.50
Change: 1.50 (0.09%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,727.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-After rocky start to year, Unilever axes 1,500 managers

Tue, 25th Jan 2022 09:22

* To create five product-focused divisions

* Long-planned revamp comes after failed bid for GSK unit

* Comes amid news of stakebuilding by activist investor
(Adds investor comment)

By Richa Naidu and Pushkala Aripaka

LONDON, Jan 25 (Reuters) - Unilever will cut about
1,500 management jobs and reshape its business to focus on five
main product areas as it tries to boost growth after a failed
acquisition and with an activist investor to appease.

The maker of Dove soap and Magnum ice cream, which employs
about 149,000 people worldwide, said on Tuesday it would focus
on beauty and wellbeing, personal care, home care, nutrition,
and ice cream.

The move, which Unilever said had been in the works for a
year, echoes the reshaping by rival Procter & Gamble (P&G)
three years ago https://www.reuters.com/article/us-procter-gamble-strategy-idUKKCN1ND37M.

"Moving to five category-focused business groups will enable
us to be more responsive to consumer and channel trends, with
crystal-clear accountability for delivery," Unilever CEO Alan
Jope said.

Unilever, whose shares have fallen by about a quarter from
their record high in 2019, last week effectively abandon https://www.reuters.com/business/retail-consumer/unilever-says-it-will-not-increase-50-bln-pound-offer-gsk-consumer-business-2022-01-19ed
plans to buy GlaxoSmithKline's (GSK) consumer
healthcare business for 50 billion pounds ($67 billion).

Its proposal, rejected by GSK, was widely criticised by
investors as being a costly and risky distraction from dealing
with pressing challenges to the business, such as surging
inflation in emerging markets and weakness in healthy foods.

Days later, reports also emerged activist investor Nelson
Peltz's Trian Partners had been building a stake in Unilever,
mirroring a previous investment and push for change at P&G and
other consumer goods companies. Trian has not confirmed a stake
in Unilever.

At P&G, Trian sought to improve the Tide detergent maker's
shrinking market share, low organic sales growth, aging brands,
bureaucracy and excessive structural costs, among other things.
Peltz also pushed for P&G's decision to restructure its business
into fewer units - similar to Unilever's new plan.

"Unilever operates in different product categories so it is
unclear if this same strategy is enough to get growth back and
over what time scale. Typically this takes years rather than
months," Tineke Frikkee, fund manager at Unilever investor
Waverton Investment Management, said.

POOR PERFORMANCE

Unilever, which is expected by analysts to next month report
a decline in full-year net income, has struggled through the
pandemic https://www.reuters.com/business/retail-consumer/unilever-margins-spotlight-inflation-surges-2021-10-20
with rising raw material, labour and transport costs. Its
exposure to certain foods and emerging markets - where inflation
is rising sharply - has also put it at a disadvantage versus
rivals P&G and Nestle.

As Unilever continues to lag, investors have grown
frustrated. On Thursday, British fund manager Terry Smith
criticised the company in a letter to his Fundsmith LLP
investors, calling the lost GSK deal a "near death experience"
and urging management to focus on strengthening performance.

"Unilever management's response to its poor performance has
been to utter meaningless platitudes to which it has now
attempted to add major M&A activity," Smith wrote.

GlobalData analyst Ramsey Baghdadi said Unilever would do
better to focus on strengthening its current product ranges and
reaching new customers, instead of diversifying into other
sectors such as healthcare - as seen in the GSK bid.

Unilever, which traces its roots to a small soap business in
1880s Britain, said it did not expect factory workers to be
impacted by its restructuring. There will be 15% fewer senior
management roles and 5% fewer junior management roles, however.

"While today’s news may not be directly connected to the
company’s failed GSK offer, the timing is unfortunate," Sean
Moran, restructuring specialist at law firm Shakespeare
Martineau, said. "When confidence in a business is low, drastic
decisions must often be made."

(Reporting by Richa Naidu in London and Pushkala Aripaka in
Bengaluru
Editing by Mark Potter)

More News
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.